Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001144204-19-008093
Filing Date
2019-02-14
Accepted
2019-02-14 16:01:49
Documents
4
Group Members
D. E. SHAW & CO., L.L.C.DAVID E. SHAW

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G/A tv512977_sc13ga.htm SC 13G/A 58449
2 EXHIBIT 1 tv512977_ex-1.htm EX-99.1 6497
3 EXHIBIT 2 tv512977_ex-2.htm EX-99.2 6543
4 EXHIBIT 3 tv512977_ex-3.htm EX-99.3 5274
  Complete submission text file 0001144204-19-008093.txt   78450
Mailing Address 1166 AVENUE OF THE AMERICAS NINTH FLOOR NEW YORK NY 10036
Business Address 1166 AVENUE OF THE AMERICAS NINTH FLOOR NEW YORK NY 10036 2124780000
D. E. SHAW & CO, L.P. (Filed by) CIK: 0001009268 (see all company filings)

EIN.: 133695715 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Subject) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-89137 | Film No.: 19605879
SIC: 2834 Pharmaceutical Preparations